Skip To Main Content
Este sitio web está dirigido exclusivamente a profesionales de la salud en Colombia, Perú, Ecuador, Pacífico y el Caribe
Campus
  • Podcast
  • RECSA
Campus
  • Podcast
  • RECSA
View Full Results

Áreas terapeúticas

Descubra la más reciente actualización sobre la evidencia científica y los datos basados en la vida real que se han recopilado en el campo de la epidemiología. Esta información incluye detalles sobre la carga que estas enfermedades imponen a las personas y a la sociedad en general, así como los métodos de control que se están implementando para hacer frente a estas situaciones.

También se aborda el impacto económico que tienen enfermedades como asma grave, cardiovascular, dermatitis atópica, diabetes o enfermedades raras, etc., en la vida de nuestra población. Estos elementos son fundamentales para comprender la magnitud del problema y para desarrollar estrategias efectivas que ayuden a mejorar la salud pública.

Ordenar por

Patología

Limpiar filtro
  • Filtros
EOE Pediatric - Unmasking the Hidden Symptoms

EOE Pediatric - Unmasking the Hidden Symptoms

Ver más
Importance of assessing key disease domains in EOE

Importance of assessing key disease domains in EOE

Ver más
Daily Burden of CRSwNP

Daily Burden of CRSwNP

Ver más
EOE Pediatric - Unmasking the Hidden Symptoms

EOE Pediatric - Unmasking the Hidden Symptoms

Ver más
Phòng Ngừa Bệnh Do Vi Khuẩn Và Virus Lây Lan Qua Đường Hô Hấp Và Vai Trò Không Thể Thiếu Của Vắc-xin

Phòng Ngừa Bệnh Do Vi Khuẩn Và Virus Lây Lan Qua Đường Hô Hấp Và Vai Trò Không Thể Thiếu Của Vắc-xin

Ver más
Rare diseases : Dried Blood Spot (DBS)

Rare diseases : Dried Blood Spot (DBS)

DBS is a form of biosampling in which blood samples collected from a finger-prick lancet are blotted and dried on filter paper.1

These samples are then sent to analytical laboratories to be analysed using a variety of methods such as enzyme assays and polymerase chain reaction (PCR).2,3

Ver más
Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results<sup>1</sup>

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

Ver más
Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results<sup>1</sup>

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

Ver más
Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results<sup>1</sup>

Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

Ver más
DERM 360° Roundtable: Patient Reported Outcome Measures (PROMs) in Clinical Practice

DERM 360° Roundtable: Patient Reported Outcome Measures (PROMs) in Clinical Practice

3rd of December 2024

Ver más
DERM 360° Roundtable: Patient Reported Outcome Measures (PROMs) in Clinical Practice

DERM 360° Roundtable: Patient Reported Outcome Measures (PROMs) in Clinical Practice

3rd of December 2024

Ver más
Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results<sup>1</sup>

LIBERTY studieprogram på atopisk eksem

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

Ver más

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

 

MAT-CO-2400825 V1.0 03/2024